NEXTGEN BIOSCIENCE Trademark

Trademark Overview

On Thursday, June 25, 2020, a trademark application was filed for NEXTGEN BIOSCIENCE with the United States Patent and Trademark Office. The USPTO has given the NEXTGEN BIOSCIENCE trademark a serial number of 79291661. The federal status of this trademark filing is REPORT COMPLETED SUSPENSION CHECK - CASE STILL SUSPENDED as of Monday, August 12, 2024. This trademark is owned by NEXTGEN Bioscience. The NEXTGEN BIOSCIENCE trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Drug discovery services; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; research and development in the field of pharmaceuticals and biotechnology; laboratory research in the field of pharmaceuticals; pharmaceutical products development; consultancy relating to pharmaceutical research and development; pharmaceutical research and development; research of pharmaceuticals; clinical testing of medicines; clinical research studies of medicines; pharmaceutical products evaluation; pharmaceutical drug development services; consultancy pertaining to pharmacology; medical laboratories; medical research studies; research and development of technology for medicinal chemical manufacturing; medicine research; testing of pharmaceuticals; research in the field of medical products; providing information on the testing, inspection, and research of medical products
nextgen bioscience

General Information

Serial Number79291661
Word MarkNEXTGEN BIOSCIENCE
Filing DateThursday, June 25, 2020
Status654 - REPORT COMPLETED SUSPENSION CHECK - CASE STILL SUSPENDED
Status DateMonday, August 12, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements

NOT AVAILABLE"BIOSCIENCE"
Goods and ServicesDrug discovery services; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; research and development in the field of pharmaceuticals and biotechnology; laboratory research in the field of pharmaceuticals; pharmaceutical products development; consultancy relating to pharmaceutical research and development; pharmaceutical research and development; research of pharmaceuticals; clinical testing of medicines; clinical research studies of medicines; pharmaceutical products evaluation; pharmaceutical drug development services; consultancy pertaining to pharmacology; medical laboratories; medical research studies; research and development of technology for medicinal chemical manufacturing; medicine research; testing of pharmaceuticals; research in the field of medical products; providing information on the testing, inspection, and research of medical products

Classification Information

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateMonday, August 17, 2020
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameNEXTGEN Bioscience
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressKR

Trademark Events

Event DateEvent Description
Saturday, October 17, 2020NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Thursday, August 13, 2020SN ASSIGNED FOR SECT 66A APPL FROM IB
Monday, August 17, 2020NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Friday, August 21, 2020APPLICATION FILING RECEIPT MAILED
Monday, September 28, 2020ASSIGNED TO EXAMINER
Friday, October 16, 2020NON-FINAL ACTION WRITTEN
Monday, November 9, 2020NON-FINAL ACTION (IB REFUSAL) WITHDRAWN FOR REVIEW
Monday, November 16, 2020NON-FINAL ACTION WRITTEN
Tuesday, November 17, 2020NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Friday, December 4, 2020REFUSAL PROCESSED BY MPU
Friday, December 4, 2020NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Saturday, December 26, 2020REFUSAL PROCESSED BY IB
Friday, June 4, 2021TEAS RESPONSE TO OFFICE ACTION RECEIVED
Friday, June 4, 2021CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, June 4, 2021TEAS/EMAIL CORRESPONDENCE ENTERED
Friday, June 4, 2021TEAS CHANGE OF CORRESPONDENCE RECEIVED
Friday, June 4, 2021ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Friday, June 4, 2021TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Friday, June 4, 2021APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Monday, December 20, 2021REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Sunday, February 6, 2022NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Friday, June 4, 2021TEAS CHANGE OF OWNER ADDRESS RECEIVED
Friday, June 4, 2021TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Thursday, June 10, 2021SUSPENSION LETTER WRITTEN
Thursday, June 10, 2021LETTER OF SUSPENSION E-MAILED
Thursday, June 10, 2021NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Wednesday, January 19, 2022NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Wednesday, January 19, 2022NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Thursday, August 10, 2023REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Monday, August 12, 2024REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Wednesday, February 14, 2024REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Friday, July 8, 2022REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Saturday, July 23, 2022NEW REPRESENTATIVE AT IB RECEIVED
Saturday, July 30, 2022CHANGE OF NAME/ADDRESS REC'D FROM IB
Thursday, January 26, 2023REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED

Related Keywords

bioscience nextgen research development medical pharmaceuticals pharmaceutical field products testing clinical medicines